Peptide Approaches to COPD: Research Directions
Respiratory Peptides
6 peptide classes
At least six distinct classes of peptides are under investigation for different aspects of COPD, from antimicrobial defense to cachexia management.
Atanasova & Reznikov, Respiratory Research, 2018
Atanasova & Reznikov, Respiratory Research, 2018
View as imageChronic obstructive pulmonary disease (COPD) affects over 300 million people worldwide and remains the third leading cause of death globally. Current treatments (bronchodilators, corticosteroids, phosphodiesterase inhibitors) manage symptoms but do not reverse the underlying lung tissue destruction. Peptide-based approaches to COPD are being explored across multiple fronts: antimicrobial peptides that defend against the infections driving acute exacerbations, neuropeptides that modulate airway inflammation, immunomodulatory peptides that restore immune function, and metabolic peptides that address the cachexia and muscle wasting common in advanced disease. None have reached standard clinical use for COPD, but the research directions are distinct and active. For context on how the nervous system drives airway inflammation more broadly, see our pillar article on neurogenic inflammation in airways.
Key Takeaways
- Substance P, CGRP, and VIP are neuropeptides that regulate airway inflammation, bronchoconstriction, and mucus secretion in COPD, often in opposing directions (Atanasova & Reznikov, 2018)
- COPD patients with lower plasma cathelicidin (LL-37) levels had worse lung function (lower FEV1) in a cohort of 1,609 participants (Burkes et al., 2020)
- Thymosin alpha 1 added to standard treatment improved immune markers and quality of life in acute COPD exacerbations across multiple trials (Cao et al., 2024)
- GLP-1 receptor activation restored macrophage phagocytic function and reduced inflammatory cytokines in cells from COPD patients (Huang et al., 2018)
- Ghrelin treatment improved exercise tolerance and respiratory muscle strength in cachectic COPD patients in a randomized trial of 33 participants (Miki et al., 2012)
- Pulmonary neuroendocrine cells release peptides including CGRP and gastrin-releasing peptide that influence airway remodeling in COPD (Zhang et al., 2025)
The Neuropeptide Landscape in COPD Airways
The airways are densely innervated, and neuropeptides released from sensory and motor nerve fibers play direct roles in COPD pathophysiology. Atanasova and Reznikov (2018) reviewed the involvement of neuropeptides across three major obstructive airway diseases: asthma, COPD, and cystic fibrosis.[1]
Three neuropeptide families dominate the COPD picture:
Substance P and tachykinins are released from C-fiber sensory neurons and drive neurogenic inflammation: bronchoconstriction, mucus hypersecretion, vasodilation, and plasma extravasation. COPD airways show increased substance P expression, and this pro-inflammatory neuropeptide contributes to the chronic inflammatory state that characterizes the disease. For a deeper look at how substance P amplifies pain and inflammation more broadly, see our article on neuropeptides in asthma.
Calcitonin gene-related peptide (CGRP) is co-released with substance P from sensory nerves. CGRP is a potent vasodilator and also modulates immune cell function in the airways. Zhang et al. (2025) reviewed how pulmonary neuroendocrine cells (PNECs) release CGRP and gastrin-releasing peptide (GRP) in COPD lungs, contributing to airway remodeling and mucus cell hyperplasia.[2]
Vasoactive intestinal peptide (VIP) opposes many of substance P's effects. VIP is a bronchodilator, vasodilator, and anti-inflammatory peptide. Said (2008) identified VIP as a key modulator of pulmonary vascular remodeling, with VIP-knockout mice spontaneously developing features of pulmonary arterial hypertension.[3] VIP also inhibits macrophage inflammatory cytokine production and promotes regulatory T-cell function, both relevant to COPD's chronic inflammatory milieu. For more on VIP's bronchodilatory properties, see our article on VIP and bronchodilation.
The challenge with neuropeptide therapies is delivery. These peptides degrade rapidly, and achieving therapeutic concentrations in the lungs without systemic side effects has limited clinical translation.
Antimicrobial Peptides and COPD Lung Defense
COPD lungs are chronically colonized by bacteria (Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis), and acute exacerbations are frequently triggered by new infections. The endogenous antimicrobial peptide system is the first line of defense against these pathogens, and its dysfunction may contribute to COPD progression.
Aarbiou et al. (2002) reviewed the role of defensins in inflammatory lung disease.[4] Human beta-defensins are produced by airway epithelial cells and provide broad-spectrum antimicrobial activity. In COPD, chronic inflammation alters defensin expression, potentially creating a permissive environment for bacterial colonization.
Tjabringa et al. (2005) characterized LL-37, the only human cathelicidin, as a multifunctional peptide in lung infection and inflammation.[5] Beyond direct antimicrobial killing, LL-37 recruits immune cells to infection sites, promotes wound healing, and modulates inflammatory responses. In the airways, it is produced by epithelial cells and neutrophils.
Burkes et al. (2020) provided the strongest clinical evidence connecting antimicrobial peptides to COPD outcomes.[6] Analyzing data from 1,609 participants in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS), they found that plasma cathelicidin levels were independently associated with lung function. Lower cathelicidin predicted lower FEV1 (the standard measure of airflow obstruction in COPD). This association held after adjusting for age, sex, BMI, smoking status, and other confounders.
The implication is that antimicrobial peptide deficiency may contribute to the cycle of infection, inflammation, and tissue destruction that drives COPD progression. Whether exogenous antimicrobial peptide supplementation could break this cycle remains untested in COPD clinical trials.
Mucosal Immune Dysfunction: Where Peptides Fit
De Fays et al. (2023) examined mucosal immune alterations at the earliest stages of COPD tissue destruction.[7] Using surgical lung specimens, they characterized the mucosal immune landscape across the spectrum from small airway changes to emphysema. The study found that immune dysregulation precedes and accompanies tissue destruction, with altered expression of antimicrobial peptides, cytokines, and immune cell populations.
This work suggests that peptide-based interventions might be most effective early in COPD progression, before extensive tissue destruction has occurred. The mucosal immune system in COPD airways shows specific deficits that peptides could theoretically address: reduced antimicrobial defense, impaired mucociliary clearance, and dysregulated inflammatory signaling.
Thymosin Alpha 1: Immunomodulation for Acute Exacerbations
Thymosin alpha 1 (Ta1), originally isolated from the thymus gland, has been the most clinically studied immunomodulatory peptide for COPD. Its mechanism involves enhancing T-cell maturation, stimulating dendritic cell activation, and promoting a balanced Th1/Th2 immune response.
Jia et al. (2015) conducted one of the earlier clinical studies, adding thymosin alpha 1 to routine treatment in patients with acute exacerbation of COPD (AECOPD).[8] They found that the combination inhibited inflammatory reactions and improved quality of life compared to routine treatment alone, with improvements in CD4/CD8 ratios and reductions in inflammatory markers including C-reactive protein and IL-6.
Cao et al. (2024) conducted a systematic review of thymosin alpha 1 for AECOPD, analyzing data across multiple randomized controlled trials.[9] Their meta-analysis found that Ta1 supplementation improved immune markers (CD4+ T-cell counts, CD4/CD8 ratio), reduced inflammatory cytokines, and improved clinical outcomes including length of hospital stay. The evidence base is strongest from Chinese clinical trials, and international replication in larger, multi-center trials has not yet occurred.
The rationale for thymosin alpha 1 in COPD is compelling: the disease involves progressive immune dysfunction, with declining T-cell function, impaired macrophage phagocytosis, and increased susceptibility to infection. A peptide that can partially restore immune competence could reduce exacerbation frequency, which is a major driver of COPD mortality and healthcare costs.
GLP-1 Receptor Agonists: An Unexpected Connection
The metabolic peptide drug class most associated with diabetes and obesity has an emerging connection to COPD. Huang et al. (2018) demonstrated that GLP-1 receptor activation with liraglutide ameliorated dysfunctional immunity in COPD patients.[10]
The study found that macrophages from COPD patients showed impaired phagocytic function, a key defect in COPD innate immunity. Treatment with the GLP-1R agonist liraglutide restored macrophage phagocytosis and reduced the production of pro-inflammatory cytokines including TNF-alpha and IL-6. GLP-1 receptors are expressed on multiple immune cell types, and their activation appears to shift macrophages from a pro-inflammatory M1 phenotype toward a more resolving M2 phenotype.
This has practical implications because many COPD patients have comorbid type 2 diabetes or obesity, conditions for which GLP-1 agonists are already prescribed. Whether the immune-restoring effects observed in vitro translate to reduced exacerbations or improved lung function in COPD patients taking GLP-1 agonists for metabolic indications is an active area of investigation.
Ghrelin for COPD Cachexia
Up to 40% of patients with advanced COPD develop cachexia: involuntary weight loss, muscle wasting, and reduced exercise tolerance that independently predict mortality. Ghrelin, the hunger hormone produced primarily by stomach cells, has anabolic and anti-inflammatory properties that make it a candidate for addressing this complication.
Miki et al. (2012) conducted a multicenter, randomized, double-blind trial of ghrelin treatment in cachectic COPD patients.[11] Thirty-three patients received either intravenous ghrelin or placebo for 3 weeks alongside pulmonary rehabilitation. The ghrelin group showed improved exercise tolerance (measured by 6-minute walk distance) and increased respiratory muscle strength. Body composition showed trends toward lean mass gain, though the small sample size limited statistical power.
The trial demonstrated that ghrelin's effects in COPD go beyond appetite stimulation. Ghrelin has direct anti-inflammatory effects in the lungs, reduces oxidative stress, and promotes muscle protein synthesis through GH-dependent and GH-independent pathways. The challenge is the route of administration (intravenous) and the short half-life of native ghrelin, which requires either continuous infusion or the development of longer-acting analogs.
Why Peptide Therapies Face Unique Delivery Challenges in COPD
COPD airways present specific obstacles that complicate peptide drug delivery. The damaged epithelial barrier, excess mucus production, chronic bacterial biofilms, and altered pH all affect how peptides behave once they reach the lungs.
Inhaled delivery is the most logical route for lung-targeted peptides, but most peptides are too large for standard metered-dose inhalers and too fragile for nebulization without degradation. VIP clinical trials for pulmonary hypertension used specialized inhalation devices, and even then, achieving consistent dosing was a challenge. Intranasal or inhaled delivery of antimicrobial peptides faces the additional problem that the mucus layer trapping bacteria also traps the therapeutic peptides before they can reach their targets.
Systemic delivery (intravenous or subcutaneous) avoids the lung delivery problem but introduces new ones. Peptides administered systemically must survive degradation in the blood, reach therapeutic concentrations in the lungs, and avoid off-target effects in other organs. The ghrelin trial by Miki et al. used intravenous administration, which is impractical for a chronic disease requiring long-term treatment.
Emerging approaches include pegylation to extend peptide half-life, lipid nanoparticle encapsulation for inhaled delivery, and development of small-molecule mimetics that reproduce the key peptide interactions without the delivery limitations. None have yet reached clinical testing in COPD, but the field is active.
What the Evidence Supports and What It Does Not
The peptide landscape for COPD is broad but shallow. Multiple peptide classes show biological rationale and early evidence, but none have advanced to the point where they would change clinical practice:
Strongest evidence: Thymosin alpha 1 for AECOPD has the most clinical trial data, including a meta-analysis, but the evidence base is geographically limited and lacks large international replication.
Most compelling mechanistic data: The antimicrobial peptide deficiency story (Burkes 2020) is epidemiologically strong, and the GLP-1 receptor immune restoration (Huang 2018) is mechanistically detailed.
Earliest stage: Neuropeptide-based therapies face fundamental delivery challenges, and stapled peptides targeting mucus secretion are in preclinical development only.
Practical overlap: GLP-1 agonists prescribed for diabetes or obesity may already be providing immune benefits to COPD patients as an unrecognized secondary effect.
The Bottom Line
Peptide approaches to COPD span at least six distinct classes: neuropeptides (substance P, CGRP, VIP) that regulate airway inflammation, antimicrobial peptides (LL-37, defensins) whose deficiency correlates with worse lung function, thymosin alpha 1 for immune restoration during acute exacerbations, GLP-1 receptor agonists that restore macrophage function, and ghrelin for cachexia management. The research is active across all fronts but remains early-stage, with thymosin alpha 1 having the most clinical trial support and antimicrobial peptide deficiency having the strongest epidemiological evidence.